Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Endo (ENDP) Lags Q1 Earnings Estimates, Cuts 2016 Outlook

By Zacks Investment ResearchStock MarketsMay 06, 2016 12:00AM ET,-cuts-2016-outlook-200128526
Endo (ENDP) Lags Q1 Earnings Estimates, Cuts 2016 Outlook
By Zacks Investment Research   |  May 06, 2016 12:00AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Endo International plc’s (NASDAQ:ENDP) first-quarter 2016 earnings of $1.08 per share fell short of the Zacks Consensus Estimate of $1.05 and decreased 8% from the year-ago period.

Revenues came in at $963.5 million in the first quarter of 2016, up 35% year over year. Revenues were however slightly below the Zacks Consensus Estimate of $964.4 million.

The Quarter in Details

The company reports results through three segments – Branded Pharmaceuticals (U.S.), Generic Pharmaceuticals (U.S.) and International Pharmaceuticals.

U.S. Branded Pharmaceuticals sales were up 9% to $309 million, primarily attributable to the acquisition of Auxilium Pharmaceuticals. While Voltaren Gel sales declined 21%, reflecting the loss of exclusivity in Mar 2016, Xiaflex sales increased 57% due to continued demand. Moreover, the Branded pain product portfolio was unfavorably impacted by public policy pressures related to the prescribing of opioids.

Endo reported generic product net sales of $583 million in the quarter, up 63%. The addition of Par Pharmaceuticals’ (Sep 2015) products and growth of certain products led to higher segmental sales. Compared to prior expectations, revenues in U.S. Generic Pharmaceuticals were adversely impacted by delayed regulatory actions related to certain 505(b)(2) products as well as increased pricing pressure due to increased competition across pain and other commoditized products within the legacy Qualitest portfolio.

The International Pharmaceuticals division contributed $71 million to total revenue in the first quarter compared with $85 million in the preceding quarter.

Cuts 2016 Outlook

Considering the impact of several headwinds including greater-than-expected price erosion across the Generics sector, delays on regulatory actions related to certain Endo products and an earlier-than-expected generic entrant for Voltaren Gel, the company lowered its outlook for 2016.

The company now expects revenues in the range of $3.87 billion to $4.03 billion (old guidance: $4.32 billion to $4.52 billion). The Zacks Consensus Estimate for revenues is currently $4.31 billion. It now expects earnings in the range of $4.50 to $4.80 per share (old guidance: $5.85 to $6.20 per share). The Zacks Consensus Estimate for earnings is currently $5.76 per share.

Gross margin is now expected in the range of approximately 59–60% (old guidance: approximately 63–65%).

Restructuring Announced

As part of Endo's ongoing Generics business integration and optimization efforts, the company announced an accelerated restructuring of its Generics product and R&D portfolio, as well as its manufacturing facility network. This restructuring is expected to result in approximately $60 million in annualized net run-rate savings by the fourth quarter of 2017 and is expected to result in the closure of the company's facility in Charlotte, NC, and a workforce reduction at its facility in Huntsville, AL. The restructuring will be completed by the third quarter of 2017.

The company, however, continues to expect to launch approximately 30 products from its newly combined pipeline in 2016 and to file approximately 25 to 30 abbreviated new drug applications with the FDA.

Meanwhile, Endo will continue to prioritize its resources across key growth products in the U.S. Branded Pharmaceuticals business – Xiaflex and Belbuca.

Our Take

Endo’s first-quarter results were discouraging with the company missing both top- and bottom-line estimates. Though Generic and Branded segment revenues increased year over year, earlier-than-expected entry of Voltaren Gel generic and continued pricing and competitive pressures across commoditized and pain products are concerning. However, restructuring initiatives undertaken by the company are encouraging. Prioritization of resources across Belbuca and Xiaflex should help drive the products’ sales.

Endo is a Zack Rank #4 (Sell) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Retrophin, Inc. (NASDAQ:RTRX) and Vital Therapies, Inc. (NASDAQ:VTL) . All three stocks sport a Zacks Rank #1 (Strong Buy).

RETROPHIN INC (RTRX): Free Stock Analysis Report

ENDO INTL PLC (ENDP): Free Stock Analysis Report

VITAL THERAPIES (VTL): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research
Endo (ENDP) Lags Q1 Earnings Estimates, Cuts 2016 Outlook

Related Articles

Endo (ENDP) Lags Q1 Earnings Estimates, Cuts 2016 Outlook

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email